GlycoEra has developed a game-changing glycoengineering platform to build a high-value pipeline of novel therapeutics. Our innovative, first-in-class product candidates will treat diseases with high unmet medical need in autoimmune, immuno-oncology, and inflammatory indications. Together with a risk-balanced and parallel development strategy, a robust discovery engine and an easy manufacturing process, we are developing a range of assets towards the clinical proof-of-concept stage.
Our team comprises specialists in glycoengineering, molecular biology, biochemistry, immunology and carbohydrate analytics, as well as experienced CMC and clinical regulatory experts. GlycoEra’s seasoned leadership team has a proven track record in advancing assets into clinical proof-of-concept, establishing global partnerships and facilitating successful corporate exits. Together with our advisors and supported by world-renowned key opinion leaders we are committed to delivering on the promise of the CustomGlycan Platform and the product development strategy.
From 2015 to 2020, Veronica was leading LimmaTech as CEO and member of the Board of Directors. LimmaTech is a spin-off of GlycoVaxyn, the company acquired by GlaxoSmithKline plc in February 2015. Veronica joined GlycoVaxyn in 2009, and during the 6 years at the firm, she held different positions, from leading the clinical and regulatory department to taking care of the business development of the company. Before joining GlycoVaxyn, she held leading roles in medical technology and biotechnology companies, including EndoArt SA and Allergan Inc, focused on clinical R&D and international regulatory affairs. Veronica holds an engineering degree from the Swiss Federal Institute of Technology, Zurich (ETH Zurich) and a PhD in life sciences in the field of cardiovascular biomedical engineering from the Swiss Federal Institute of Technology, Lausanne (EPFL). She is the author of several articles in research and clinical development.
Prior to GlycoEra Amir was a co-founder and CSO of LimmaTech Biologics, responsible for defining scientific strategy for development of vaccines and biotherapeutics. Prior to LimmaTech, he was Head of Discovery and a member of the management team at GlycoVaxyn AG at the time of its acquisition by GlaxoSmithKline plc in February 2015. He established the Discovery department of GlycoVaxyn in 2013 where he was responsible for the development of proprietary research projects and platforms. He has 20 years’ experience in glycobiology and glycoengineering, and pioneered several glycoengineering platforms, including vaccine bioconjugation and therapeutic CustomGlycan platforms. Amir obtained his PhD in 2005 from the University of British Columbia, Canada, followed by Post-Doctoral Fellowships at the Alberta Glycomic Center, University of Alberta and Institute of Microbiology at ETH. He is the author of several peer-reviewed articles and an inventor of several granted patents.
Dominique was a co-founder and COO of LimmaTech Biologics AG and was responsible for process and analytical development of LimmaTech’s vaccine candidates prior to his focusing on GlycoEra. He joined GlycoVaxyn AG in 2011 as Head of Process Development and Industrialization and held that position at the time of the company’s acquisition by GlaxoSmithKline plc in February 2015. Before this, he acquired significant experience in cGMP quality control, manufacturing and validation while working for more than 5 years at Cytos Biotechnology AG. Dominique holds a PhD in science from the University of Zurich and studied Adenovirus biology and its application in tumor therapy.
Momenta Pharmaceuticals was acquired by Johnson and Johnson for US $6.5 Billion in August 2020. Presently, Ganesh is mentoring, and on the board of multiple early stage companies, working with investors and management teams to translate scientific innovations, develop corporate strategy and raise capital and is a strategic advisor for Biological E Ltd, an international vaccine company. Previously, Ganesh was a research faculty member at the Harvard-MIT Division of Health Sciences and Technology and later at the MIT Division of Bioengineering. He was the Director of Bioinformatics at MIT for a multi-center project on evaluating roles of complex polysaccharides in biology.
David is Professor of Vaccinology and Immunology and Head of the Immunobiology Section at the Great Ormond Street Institute of Child Health, University College London (UCL) where he also holds the role of Institute Deputy Director for NHS Engagement. He is a Consultant Paediatric Immunologist at the Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH) where he is also Director of Clinical Research and Development.
Bill is founder and owner of BiStro Biotech Consulting LLC. Prior to retiring from Johnson & Johnson in 2016, Dr. Strohl was VP and Head, Janssen BioTherapeutics, Janssen R&D, J&J, where he headed up biologics discovery and early development. Before that, Bill was head of Biologics Research, the discovery arm of Janssen BioTherapeutics. Before joining J&J, he was at Merck and Co, leading the Biologics discovery efforts, where he was involved in two biotechnology company acquisitions.
Jim is currently Cecil and Ida Green Professor and Chair of Molecular Medicine. His current research interests include the roles of glycan binding proteins in the modulation of immune cell signaling, and the receptor specificity of mammalian and animal influenza viruses. Jim is a world-renowned pioneer in glycobiology and glycol-immunology.